C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 487/04 (2006.01) A61K 31/519 (2006.01) A61K 31/5517 (2006.01) A61P 5/40 (2006.01) C07D 235/00 (2006.01) C07D 241/00 (2006.01) C07D 243/00 (2006.01)
Patent
CA 2494636
Compounds of formula (I), provide pharmacological agents which are inhibitors of the P450 enzyme, aldosterone synthase, and thus may be employed for the treatment of aldosterone mediated conditions. Accordingly, the compounds of formula (I) may be employed for prevention, delay of progression, or treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis, and remodeling following hypertension and endothelial dysfunction. Preferred are the compounds of formula (I) which are selective inhibitors of aldosterone synthase devoid of undesirable side effects due to general inhibition of cytochrome P450 enzymes.
La présente invention concerne des composés de formule (I) constituant des agents pharmacologiques qui sont des inhibiteurs de l'enzyme P450 ou aldostérone synthase, et peuvent ainsi être utilisés pour le traitement d'états pathologiques induits par l'aldostérone. Ainsi, les composés de formule (I) peuvent être utilisés pour la prévention, le retardement de la progression, ou le traitement de l'hypokaliémie, de l'hypertension, l'insuffisance cardiaque congestive, l'insuffisance rénale, en particulier, de l'insuffisance rénale chronique, de la resténose, de l'athérosclérose, du syndrome X, de l'obésité, de la néphropathie, du syndrome de Dressler, des maladies coronariennes, de la formation accrue de collagène, de la fibrose, ainsi que du remodelage post-hypertension et post-dysfonctionnement endothélial. Les composés de formule (I) préférés sont des inhibiteurs sélectifs d'aldostérone synthase dépourvus d'effets secondaires indésirables dus à l'inhibition générale d'enzymes du cytochrome P450.
Fetherstonhaugh & Co.
Novartis Ag
LandOfFree
Organic compounds as agents for the treatment of aldosterone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Organic compounds as agents for the treatment of aldosterone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Organic compounds as agents for the treatment of aldosterone... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1452685